CTMX Q1 2020 Earnings — CytomX Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

CTMXCytomX Therapeutics, Inc.

$822M

Q1 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$50M+68.2% YoY

Gross Profit

$50M100.0% margin

Operating Income

-$3M-5.6% margin

Net Income

$12M24.6% margin

EPS (Diluted)

$0.26

QoQ Revenue Growth

+499.0%

Cash Flow

Operating Cash Flow

-$50M

Free Cash Flow

-$51M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$437M

Total Liabilities

$367M

Stockholders' Equity

$70M

Cash & Equivalents

$143M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$50M	$29M	+68.2%
Gross Profit	$50M	$29M	+68.2%
Operating Income	-$3M	-$17M	+83.1%
Net Income	$12M	-$14M	+186.4%